Zimbabwe has rejected a significant American health deal valued at 367 million US dollars (£272m) spanning five years due to Washington's request for confidential biological samples.
This rejection became public after a internal memorandum dated December was disclosed, revealing that Head of State Emmerson Mnangagwa deemed the agreement was "skewed".
A government spokesperson has since stated that the United States was seeking health data for research and profit but was unwilling to guarantee the benefits from future medical innovations.
"We must now begin the difficult and regrettable process of scaling back our support in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy noted the United States had donated more than $1.9bn for health programmes to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has urged more dialogue to reach a agreement acceptable to both sides so the nation's critical HIV treatment initiative can proceed.
Wider Context
This rejection comes after a similar situation in Kenya, where a court halted a related deal with the US following concerns were raised about the safety of citizens' health data.
Since resuming office recently, US President Donald Trump has slashed overseas assistance and closed the key foreign aid agency.
USAID had administered assistance for the American government, but Trump argued its spending was "inefficient" and his administration was seeking direct bilateral deals to enhance transparency and accountability.
As per reports, 16 nations in Africa have so far agreed to similar health pacts, representing over $18.3bn of fresh investment.
Specifics of the Declined Agreement
This assistance for Zimbabwe would have gone towards "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"It is our view this cooperation would have delivered significant advantages for the people of Zimbabwe, especially the 1.2 million currently on antiretroviral therapy via American-funded initiatives," the Ambassador said.
However, official spokesman Nick Mangwana said the arrangement was "asymmetrical".
"The proposal required Zimbabwe to provide its biological resources and data over an extended period, without any corresponding assurance of benefiting from any medical innovations – like vaccines, diagnostics, or treatments – that could result from that shared data," Mangwana explained.
"In essence, our country would provide the raw materials for scientific discovery without any assurance that the end products would be accessible to our people if a new health crisis arise."
National Interest and International Frameworks
He also noted that the American exit from the World Health Organization (WHO) and its push of bilateral deals were undermining structures previously established via the international health agency.
Mangwana cited its Pathogen Access and Benefit Sharing scheme designed to deal with future pandemics.
"This system is designed to ensure that when a country provides its data, the resulting advantages – including medicines and cures – are shared equitably, not monopolised solely by those with the capability to develop them."
The government's concerns over the US deal "must not be interpreted as opposition to America," he added.
"We are open to ongoing dialogue with our US partners on how subsequent collaboration might be designed in a manner that honours the sovereignty and dignity of both nations."
Health Experts Reaction
A leading public health body stated it recognised the government's concerns, but recommended that negotiations must proceed considering much of the country's HIV programmes were funded by external financing.
"Where technical issues arise, such as those relating to information security or implementation frameworks, these can frequently be addressed through technical clarification and mutually agreed protections," it said.
The situation highlights the continuing tensions between receiving much-needed international aid and protecting national sovereignty in an increasingly data-driven world.